INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)

Name: INTREPID (A randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of individuals with Parkinson disease; NCT01839396)
Uploaded: 2025-11-14T17:00:00+00:00
Duration: 3 min 33 s
Description: Jerrold L. Vitek, MD, PhD, Head of the Neurology Department at the University of Minnesota, Minneapolis, MN, provides an overview of the INTREPID clinical

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Bill Nye on Ataxia, Family Risk, and the Search for Answers
Bill Nye on Ataxia, Family Risk, and the Search for Answers
Movement Disorders
Bill Nye on Ataxia, Family Risk, and the Search for Answers
Bill Nye; Lauren Moore, PhD
Bill Nye; Lauren Moore, PhD
Advanced Parkinson Disease: Treatment Approaches
Advanced Parkinson Disease: Treatment Approaches
Movement Disorders
Advanced Parkinson Disease: Treatment Approaches
John B. Sanderson, MD; Pinky Agarwal, MD, FAAN
John B. Sanderson, MD; Pinky Agarwal, MD, FAAN
Practical MRI in Neurology: Use Cases, Technologies, and Opportunities for Outpatient Clinics
Practical MRI in Neurology: Use Cases, Technologies, and Opportunities for Outpatient Clinics
Imaging & Testing
Practical MRI in Neurology: Use Cases, Technologies, and Opportunities for Outpatient Clinics
Joseph Fritz, PhD; Edmond A. Knopp, MD, DABR, FASFNR
Joseph Fritz, PhD; Edmond A. Knopp, MD, DABR, FASFNR
Special Report: 2025 Neurology FDA Drug & Device Approvals & Clearances
Special Report: 2025 Neurology FDA Drug & Device Approvals & Clearances
Alzheimer Disease & Dementias
Special Report: 2025 Neurology FDA Drug & Device Approvals & Clearances